Rapid Micro Biosystems(US:RPID)2025-11-07 11:03Revenue Performance - Total revenue for Q3 2025 increased by 3% to $7.8 million compared to $7.6 million in Q3 2024[4] - Recurring revenue rose by 32% to $4.8 million in Q3 2025, driven by record consumable revenue[4] - Service revenue increased by 12% to $2.6 million in Q3 2025 compared to $2.3 million in Q3 2024[4] - Full-year 2025 total revenue guidance raised to at least $33.0 million, assuming at least 27 Growth Direct system placements[10] Operating Performance - Gross margin improved to 9%, a 70-basis point increase from 8% in Q3 2024[8] - Total operating expenses decreased by 5% to $12.1 million in Q3 2025, down from $12.7 million in Q3 2024[6] - Net loss for Q3 2025 was $11.5 million, slightly higher than the $11.3 million loss in Q3 2024[7] Strategic Developments - The company received its largest multi-system order in history from a Top 20 global biopharma customer in October 2025[9] - The company placed five new Growth Direct systems in Q3 2025, compared to seven placements in Q3 2024[4] Financial Position - Cash, cash equivalents, and short-term investments totaled approximately $42 million as of September 30, 2025[7]